About
Oral drugs
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (41)
View allTotal Trials
41
As Lead Sponsor
39
As Collaborator
2
Total Enrollment
6,614
By Phase
PHASE2: 6PHASE1: 21PHASE3: 2PHASE2/PHASE3: 2PHASE1/PHASE2: 7
By Status
COMPLETED: 19RECRUITING: 7TERMINATED: 7WITHDRAWN: 3ACTIVE_NOT_RECRUITING: 2UNKNOWN: 2NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline40 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05690035Collaborator
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
PHASE2Withdrawn
Started: Jul 31, 2025 · Completed: Jul 31, 2025
NCT07025018Lead Sponsor
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
PHASE1Recruiting
52 participants
Started: Jul 15, 2025 · Completed: Dec 31, 2027
NCT06584032Lead Sponsor
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
PHASE3Recruiting
412 participants
Started: Dec 12, 2024 · Completed: Jun 9, 2029
NCT06671873Lead Sponsor
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
PHASE1Completed
6 participants
Started: Nov 26, 2024 · Completed: Jul 2, 2025
NCT06601504Lead Sponsor
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
PHASE2Active, not recruiting
61 participants
Started: Nov 5, 2024 · Completed: Nov 12, 2026
Locations (1)
Headquarters
Hong Kong, China
Map
Loading map...